Navigation Links
Neuralstem Secures $8 Million In Debt Financing From Hercules
Date:3/25/2013

ition, Neuralstem issued Hercules 648,798 warrants to purchase shares of Neuralstem common stock at an exercise price of $1.08 per share. The second tranche of $2 million will be made available to the company, at the company's option until September 30, 2013, subject to certain conditions. Further information with respect to the loan agreement with Hercules is contained in a Current Report on Form 8-K filed with the Securities and Exchange Commission.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities referenced herein in any jurisdiction to any person. The warrants  and underlying shares issued in connection with the transactions have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration under the Securities Act and applicable state securities laws or an applicable exemption from those registration requirements.

TriPoint Global Equities, LLC was the placement agent for the transaction.

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem completed an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig 's disease, in February 2013, and has submitted recommended Phase II trial protocol to the FDA. Neuralstem has been awarded orphan status designation by the FDA for its ALS cell therapy.

In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury, ischemic stroke and glioblastoma (brain cancer). The company
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Neuralstem Grants Licenses For Central Nervous System Therapy Surgical Devices To Cedars-Sinai Medical Center
2. Neuralstem President And CEO To Present At BIO CEO & Investor Conference 2013
3. Neuralstem to Raise $7.0 Million in Registered Direct Offering
4. Neuralstem Announces Proposed Public Offering
5. Neuralstem Grants First Licenses For CNS Therapy Surgical Devices
6. Neuralstem Announces Exercise Of Entire Over-Allotment Option By Aegis Capital Corp.
7. Seventeenth Patient Dosed in Neuralstem ALS Stem Cell Trial
8. First Patients Dosed in Ib Phase of Neuralstems NSI-189 Trial in Major Depressive Disorder
9. Sixteenth Patient Dosed In Neuralstem ALS Stem Cell Trial
10. Neuralstem Updates ALS Stem Cell Trial Progress
11. Total Artificial Heart Manufacturer SynCardia Secures $19M Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 23, 2014  SI-BONE, Inc., a medical device company ... ® a minimally invasive surgical (MIS) device indicated ... that the U.S. Patent and Trademark Office has awarded ... for the fixation and fusion of bone.  This newly ... tapered distal end that may be placed from one bone across ...
(Date:9/23/2014)... Sept. 23, 2014 Report Details ... you trends, R&D and predicted revenues Do you ... Now get the latest analysis for those cancer ... opportunities and revenue forecasts. Visiongain,s new report ... kinase inhibition and related technology. There avoid missing ...
(Date:9/23/2014)... , Sept. 23, 2014 EnzymeBioSystems (OTCBB: ... along with the process of evaluating an enzyme ... in fighting tumors. In an effort to evaluate this ... with various contract research organizations to enlist their ... the use of an antitumor natural product called ...
Breaking Medicine Technology:SI-BONE, Inc. Strengthens Patent Portfolio with the U.S. Patent and Trademark Office's Issuance of Threaded, Fenestrated Implant Method Patent 2SI-BONE, Inc. Strengthens Patent Portfolio with the U.S. Patent and Trademark Office's Issuance of Threaded, Fenestrated Implant Method Patent 3Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 2Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 3Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 4Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 5EnzymeBioSystems Announces Progress with an Enzyme Compound 2
... today reported financial results for the third quarter ended,September ... Novavax reported a net loss of $9.0 million, or ... $5.0 million net loss, or the,equivalent of $0.08 loss ... For the nine months ended September 30, 2007, the ...
... Allos,Therapeutics, Inc. (Nasdaq: ALTH ) today announced ... non-randomized, open-label, multi-center dose,escalation study of the Company,s ... tumors or non-Hodgkin,s lymphoma (NHL). "We are ... said Pablo,J. Cagnoni, M.D., Chief Medical Officer of ...
Cached Medicine Technology:Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 2Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 3Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 4Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 5Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 6Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma 2Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma 3Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma 4
(Date:9/23/2014)... The inaugural single day event in ... New Otani Tokyo Gardens in Tokyo. Clinical data scientists will ... validation. , The second single day event in China ... in Shanghai. The clinical data scientists attending this event will ... and listings, which display data collected in clinical studies and ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 "The primary purpose ... control," said an inventor from Sacramento, Ca.. "Call lights are ... or left hanging on the IV pole out of the ... the nurse call device whenever they need it, I created ... effectively position the nurse call device within easy reach. The ...
(Date:9/23/2014)... 2014 From first-hand experience, Matthew O'Farrell ... and how it can be treated. , A medically ... in 2006. His platoon sustained multiple attacks resulting in ... diagnosed with combat-related PTSD and honorably discharged from the ... I had distanced myself from my friends and family,” ...
(Date:9/23/2014)... HealthDay Reporter TUESDAY, Sept. 23, 2014 (HealthDay ... providing better care, not more care, ... A new report suggests that,s the direction the ... IMS Institute for Healthcare Informatics in Parsippany, N.J., identifies 10 ... delivery of health care and use of medicines over the ...
(Date:9/23/2014)... What information do patients need ... Forum (NQF) released a report ( http://bit.ly/1DwekE9 ), ... infographic ( http://bit.ly/1tX3lzA ) resulting from an in-depth ... patients define affordability, and what information and changes ... possible healthcare at the lowest possible cost. ...
Breaking Medicine News(10 mins):Health News:PhUSE Further Expands its Global Community Into the Asian Region 2Health News:Virtual Reality software to help treat PTSD 2Health News:Virtual Reality software to help treat PTSD 3Health News:Report Identifies Game Changers for U.S. Health Care 2Health News:Report Identifies Game Changers for U.S. Health Care 3Health News:Finding Affordable Care: Asking the Right Question is Key 2
... consumption dropped, study found , FRIDAY, June 18 (HealthDay ... may reduce consumption and help lower levels of obesity ... suggests. , Researchers examined what happened during a time ... in Boston increased the price of regular soft drinks ...
... , ... Life sell an extensive range of vitamins supplements and nutritional supplements by top manufacturers ... ... Established in 1999, Vitamins for Life (vitaminsforlife.co.uk) supplies practitioner-grade nutritional supplements that ...
... 2010: Systemic Lupus Erythematosus (SLE) patients from Brazil ... that their rheumatic conditions negatively affect their emotional ... today at EULAR 2010, the Annual Congress of ... Furthermore, findings of the French study specifically revealed ...
... The effects of Systemic Lupus Erythematosus (SLE) may differ ... results of a new study presented today at EULAR ... Rheumatism in Rome, Italy. In particular, the study reinforced ... European subpopulations. Results from a Europe-wide study, involving ...
... Kids Bento ... , ... 18, 2010 -- School’s about to start and so is the mad morning scramble of ... kids’ bento boxes , from Laptop Lunches. They’re ideal for packing fun, wholesome, ...
... ... 360 Degree Guarantee and provide consumers with coverage that extends past the original manufacturer labor ... standard warranty. , ... 18, 2010 -- Treadmill Doctor has announced the introduction of their new 360 ...
Cached Medicine News:Health News:People May Skip Soft Drinks Rather Than Pay More 2Health News:Natural Health Online Retailer VitaminsForLife.co.uk Expands Inventory to Meet UK Demands 2Health News:Natural Health Online Retailer VitaminsForLife.co.uk Expands Inventory to Meet UK Demands 3Health News:Sex lives of patients are negatively affected by rheumatoid arthritis and SLE 2Health News:Sex lives of patients are negatively affected by rheumatoid arthritis and SLE 3Health News:Kids' Lunchboxes Go Bento for Easy Back to School Lunch Making, Thanks to Laptop Lunches 2Health News:Treadmill Doctor 360 Degree Guarantee Extended Service Plans 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: